Pulmatrix (PULM) Trading Up 12.3%

Pulmatrix Inc (NASDAQ:PULM) was up 12.3% during mid-day trading on Monday . The stock traded as high as $1.95 and last traded at $1.83. Approximately 951,791 shares changed hands during trading, an increase of 15% from the average daily volume of 830,941 shares. The stock had previously closed at $1.63.

Several equities research analysts recently issued reports on PULM shares. HC Wainwright reaffirmed a “buy” rating on shares of Pulmatrix in a report on Monday, November 19th. ValuEngine lowered shares of Pulmatrix from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd.

The firm has a market capitalization of $13.57 million, a price-to-earnings ratio of -0.37 and a beta of 1.64.

Pulmatrix (NASDAQ:PULM) last posted its earnings results on Tuesday, February 19th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.20) by $0.92. Analysts forecast that Pulmatrix Inc will post -5.7 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.com-unik.info/2019/03/18/pulmatrix-pulm-trading-up-12-3.html.

About Pulmatrix (NASDAQ:PULM)

Pulmatrix, Inc, a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD).

Recommended Story: LIBOR

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit